Persistent Benefit of Long-Acting Cabotegravir for PrEP

After the first unblinded year of HTPN 083, injectable cabotegravir continued to maintain superior efficacy over oral TDF/FTC for preventing HIV infection.

In its 153-week blinded analysis, the HIV Prevention Trials Network (HPTN) trial 083 demonstrated that injectable cabotegravir (CAB) was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) for preexposure prophylaxis (PrEP) in cisgender men and transgender women who have sex with men (NEJM JW Infect Dis Aug 16 2021 and N Engl J Med 2021; 385:595). One year after the trial's unblinding, Landovitz and colleagues now present HPTN 083 results in 3290 participants (1663 [CAB] and 1627 [TDF/FTC]).

HIV incidence rates per 100 person-years increased in both study groups relative to those in the blinded phase (from 0.41 to 0.82 [CAB] and from 1.29 to 2.27 [TDF/FTC]). Although adherence in both groups decreased after unbl…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Persistent Benefit of Long-Acting Cabotegravir for PrEP

Topics

Reviewing Author